Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	3/4/2005 1:03:25 PM
	Read Replies (1) of 52153

Reprieve for Iressa... Whole story: online.wsj.com Lead paragraphs... FDA Will Wait for More Data On AstraZeneca Cancer Drug DOW JONES NEWSWIRES March 4, 2005 12:00 p.m. WASHINGTON -- The Food and Drug Administration said Friday it will wait for additional data on AstraZeneca PLC's lung-cancer drug Iressa before deciding whether to pull it off the U.S. market. Richard Padzur, the head of the agency's oncology drug division, said "the FDA will not make a definitive decision on Iressa until the trial data are received and reviewed." The decision comes amid increasing scrutiny of the drug industry, which has seen several high-profile drug withdrawals in recent months. Unlike those cases, however, the questions surrounding Iressa are ones of efficacy, not safety. ...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next